Updated on 4 January 2013
Ranbaxy deploys Cegedim Relationship Management's life science compliance solution suite to cope with the compounding regulatory environment
Singapore: Ranbaxy Laboratories has deployed US-based Cegedim Relationship Management's life science compliance solution suite, including AggregateSpend360, to more efficiently, proactively and successfully respond to compounding regulatory environment.
AggregateSpend360 enables increased data visibility and features tailored to compliance functionalities. AggregateSpend360 alleviates Ranbaxy's resources and time spent meeting the PPACA's state/federal aggregate spend and disclosure reporting requirements. The solution collects and centralizes all transfers of value to practitioners, rationalizing the data into one customer view for optimal visibility.
The cloud-based solution generates reports specific to each federal/state regulation. Further, the solution features unparalleled configuration flexibility to suit Ranbaxy's distinctive business model needs, fostering cost-effectiveness now and in the future. AggregateSpend360 fully automates the compliance burden.
Ranbaxy's compliance solution suite also includes Cegedim's compliance ID Powered by OneKey, which empowers companies to satisfy aggregate spend and disclosure reporting regulations through verified medical licensure information sourced from OneKey's database of 12 million registered healthcare professionals and one million healthcare organizations. Ranbaxy is also leveraging Cegedim's BuzzeoPDMA compliance knowledge through Computer Systems Validation Services, which confirm that systems satisfy both state and federal regulatory standards.
"By aligning with Cegedim's AggregateSpend360 and their compliance suite, we are staying well ahead of the curve regarding new US legislation. Teams across the US enterprise are now empowered with the tools to better track spending, improve data, and ensure that our technology is fully compliant," said Dr Ashish Anvekar, senior director, Ranbaxy Laboratories. "Our company can achieve greater focus in providing patient-centric, quality and value-added pharmaceuticals."